. 2019 Apr 30;78(7):890–898. doi: 10.1136/annrheumdis-2018-214529

Table 2.

Change in efficacy and patient-reported outcomes 4, 8 and 12 weeks after rescue in rescued patients from RA-BEAM

	Baricitinib to baricitinib (n=35)				Adalimumab to baricitinib (n=40)
	Score at time of rescue	Change from rescue visit			Score at time of rescue	Change from rescue Visit
	Score at time of rescue	Week 4 (n=34)	Week 8 (n=33)	Week 12 (n=30)	Score at time of rescue	Week 4 (n=40)	Week 8 (n=39)	Week 12 (n=33)
DAS28-ESR	6.1 (1.3)	−0.93 (0.18)***	−1.51 (0.20)***	−1.73 (0.22)***	6.2 (1.3)	−1.38 (0.17)***	−1.69 (0.19)***	−1.92 (0.21)***
CDAI	39.3 (15.2)	−14.1 (2.1)***	−20.5 (2.2)***	−22.3 (2.3)***	36.4 (14.5)	−14.8 (2.0)***	−17.8 (2.0)***	−20.2 (2.2)***
SDAI	40.8 (16.0)	−14.1 (2.3)***	−21.0 (2.3)***	−23.1 (2.5)***	38.9 (14.5)	−16.2 (2.1)***	−19.2 (2.2)***	−21.8 (2.3)***
Patient’s assessment of pain	53.8 (21.0)	−13.1 (3.8)***	−13.8 (3.9)***	−18.3 (4.0)***	56.4 (25.4)	−14.5 (3.5) ***	−21.5 (3.6)***	−24.1 (3.7)***
HAQ-DI	1.42 (0.72)	−0.19 (0.08)*	−0.28 (0.08)***	−0.34 (0.09)***	1.46 (0.66)	−0.37 (0.07) ***	−0.47 (0.08)***	−0.49 (0.09)***
CRP, mg/L	14.9 (23.5)	−0.45 (4.35)	−4.79 (4.49)	−8.50 (5.04)	25.3 (29.8)	−13.50 (4.00)***	−14.10 (4.13)***	−16.00 (4.69)***
ESR, mm/h	36.5 (27.7)	0.71 (3.40)	−4.49 (4.16)	−5.05 (4.76)	51.9 (35.4)	−16.60 (3.16)***	−21.80 (3.85)***	−19.06 (4.48)***

Score at the time of rescue data are mean (SD); change from baseline data is LSM (SE).

*p≤0.05; **p≤0.01; ***p≤0.001 from within-group mean change from the last visit prior to rescue using MMRM.

CDAI, Clinical Disease Activity Index;CRP, C reactive protein; DAS28-ESR, disease activity score using 28-joint count with erythrocyte sedimentation rate;ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index;LSM, least squares mean;MMRM, mixed-effects model repeated measures;SDAI, Simplified Disease Activity Index.